肝血管瘤热消融:多中心长期结局经验
回顾性分析6家医院2011年10月至2021年2月接受热消融的357例患者共378个肝血管瘤,技术成功率100.0%,完全消融率95.5%,主要并发症率2.0%,中位随访67个月,96.4%的症状性患者症状完全消失,作者认为热消融是安全、可行、有效的治疗选择。
要点
- 378个肝血管瘤(5.0-21.2 cm)热消融技术成功率100.0%,完全消融率95.5%(361/378)。
- 17个(4.5%)不完全消融者表现为周边 rim 细微强化。
- 主要并发症率2.0%(7/357),中位随访67个月(范围12-124个月)。
核心结论
- 在合理的消融策略与综合治疗措施下,热消融可能是肝血管瘤安全、可行、有效的治疗选择。
研究设计与样本
- 回顾性研究,纳入6家医院2011年10月至2021年2月357例患者共378个肝血管瘤;252例患者273个包膜下血管瘤行腹腔镜热消融,105例患者105个肝实质内血管瘤行CT引导经皮消融。
关键影像表现/征象
- 378个肝血管瘤中369个接受1次消融,9个接受2次消融。
- 17个(4.5%)不完全消融的血管瘤表现为周边 rim 细微强化。
- 消融后病灶逐渐缩小,11.4%的血管瘤随时间几乎完全消失(P < 0.01)。
诊断标准与关键数值
- 技术成功率为100.0%。
- 完全消融率为95.5%(361/378),不完全消融率为4.5%(17/378)。
- 主要并发症率为2.0%(7/357)。
- 224例有血管瘤相关症状的患者中,216例(96.4%)症状完全消失,8例(3.6%)症状改善。
临床应用与阅片要点
- 对于包膜下血管瘤可采用腹腔镜热消融,肝实质内血管瘤可采用CT引导经皮消融。
- 消融后不完全消融可表现为周边 rim 细微强化,需与残留病灶鉴别。
- 消融后病灶可逐渐缩小,部分可几乎完全消失,随访中可观察到这一转归。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Thermal ablation, currently used extensively for liver tumors, also has been applied. successfully to hepatic hemangioma; however, it is still considered experimental because previous studies have comprised small sample sizes with short follow-up periods.
PURPOSE: We aimed to investigate the effectiveness, safety, and long-term outcomes of thermal ablation for hepatic hemangioma.
MATERIALS AND METHODS: From October 2011 to February 2021, the data of 357 patients with 378 hepatic hemangiomas treated by thermal ablation at six hospitals were analyzed in this retrospective study. The technical success, safety, and long-term follow-up results were analyzed.
RESULTS: A total of 252 patients (mean age, 49.2 ± 10.5 years) with 273 subcapsular hemangiomas underwent laparoscopic thermal ablation, whereas 105 patients with 105 hemangiomas located in the liver parenchyma underwent CT-guided percutaneous ablation. Of the 378 hepatic hemangiomas (5.0-21.2 cm), 369 lesions were subjected to one session of ablation, while 9 lesions were subjected to two sessions of ablation. Technical success was achieved in 100.0% of cases. Complete ablation was achieved in 361 of 378 hemangiomas (95.5%), while 17 hemangiomas (4.5%) were incompletely ablated, showing subtle enhancement at the peripheral rim. The major complication rate was 2.0% (7/357). The median follow-up period was 67 months (range, 12-124 months). Of the 224 patients with hemangioma-related symptoms, 216 demonstrated complete disappearance of symptoms (96.4%), while 8 were ameliorated (3.6%). Ablated lesion shrinkage was progressive, and 11.4% of hemangiomas almost completely disappeared over time (P < 0.01).
CONCLUSION: With a reasonable ablation strategy and comprehensive treatment measurements, thermal ablation could be a safe, feasible, and effective treatment option for hepatic hemangioma.
引用
- Xu, Wu, Kong, et al. Thermal ablation of hepatic hemangioma: A multi-center experience with long-term outcomes. Eur J Radiol. 2023. PMID: 37172442. doi:10.1016/j.ejrad.2023.110842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。